FSHR and neoplasm: Yang et al. evidenced the efficient targeting of breast cancer metastasis in an experimental murine model featuring GO conjugated with a monoclonal antibody (mAb) against follicle-stimulating hormone receptor (FSHR), a highly selective tumor vasculature marker in both primary and metastatic tumors [215].